Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Immortal Style: Closet Staples for Each Age - 2Behind every perfect holiday memory is a mom on the brink
- 3The most effective method to Use an Internet Showcasing Degree for Advanced Predominance
- 4How did humans evolve, and will we evolve more?
- 5From Specialist to Proficient Picture taker: Individual Triumphs
- It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing
- Figure out How to Alter Your Volvo XC40 for Further developed Solace
- Find the Force of The ability to understand anyone on a deeper level: Improving Mindfulness and Connections
- Turning into a Sharp Financial backer: Individual budget Wins
- Don’t let food poisoning crash your Thanksgiving dinner
- Instructions to Improve Your Mental Exploration with Cutting edge Measurements
- The Incomparable Advanced cameras: Which One Will Win?
- An Extended period of Voyaging Carefully: the World with Reason
- 10 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
